Uscom
Market Cap
AU$59.0m
Last Updated
2020/02/17 10:35 UTC
Data Sources
Company Financials
Executive Summary
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide.
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 3 more risks
Snowflake Analysis
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Uscom's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: UCM's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-19.8%
UCM
-1.6%
AU Medical Equipment
1.5%
AU Market
1 Year Return
196.2%
UCM
36.7%
AU Medical Equipment
15.6%
AU Market
Return vs Industry: UCM exceeded the Australian Medical Equipment industry which returned 35.4% over the past year.
Return vs Market: UCM exceeded the Australian Market which returned 16.1% over the past year.
Shareholder returns
| UCM | Industry | Market | |
|---|---|---|---|
| 7 Day | -19.8% | -1.6% | 1.5% |
| 30 Day | 175.0% | 1.3% | 0.4% |
| 90 Day | 175.0% | 6.5% | 4.1% |
| 1 Year | 196.2%196.2% | 39.0%36.7% | 20.6%15.6% |
| 3 Year | 75.0%75.0% | 80.7%72.9% | 37.1%18.7% |
| 5 Year | 102.6%102.6% | 121.3%104.0% | 50.9%17.1% |
Price Volatility Vs. Market
How volatile is Uscom's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
What Kind Of Shareholder Owns Most Uscom Limited (ASX:UCM) Stock?2 months ago | Simply Wall St
Is Uscom Limited's (ASX:UCM) CEO Pay Justified?2 months ago | Simply Wall St
Have Insiders Been Buying Uscom Limited (ASX:UCM) Shares?Valuation
Is Uscom undervalued compared to its fair value and its price relative to the market?
15.19x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate UCM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate UCM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: UCM is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: UCM is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UCM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UCM is overvalued based on its PB Ratio (15.2x) compared to the AU Medical Equipment industry average (4.4x).
Next Steps
Future Growth
How is Uscom forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
17.8%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uscom has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Uscom's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Uscom competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Uscom performed over the past 5 years?
-4.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UCM is currently unprofitable.
Growing Profit Margin: UCM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: UCM is unprofitable, and losses have increased over the past 5 years at a rate of -4.8% per year.
Accelerating Growth: Unable to compare UCM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UCM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.6%).
Return on Equity
High ROE: UCM has a negative Return on Equity (-39.83%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Uscom's financial position?
Financial Position Analysis
Short Term Liabilities: UCM's short term assets (A$2.9M) exceed its short term liabilities (A$613.0K).
Long Term Liabilities: UCM's short term assets (A$2.9M) exceed its long term liabilities (A$38.0K).
Debt to Equity History and Analysis
Debt Level: UCM is debt free.
Reducing Debt: UCM has not had any debt for past 5 years.
Balance Sheet
Inventory Level: UCM has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if UCM's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UCM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: UCM has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4% each year
Next Steps
Dividend
What is Uscom's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate UCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate UCM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UCM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UCM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UCM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
AU$251k
CEO Compensation
CEO
Rob Phillips (66yo)
AU$250,765
Compensation
Dr. Robert Allan Phillips, also known as Rob, Ph.D.(Med), MPhil (Med), FASE, DMU, AMS, FIR, is the Founder of Uscom Limited and serves as its Chief Scientist. Dr. Phillips has been the Chief Executive Offi ...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD168.49K) is below average for companies of similar size in the Australian market ($USD254.67K).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.
Top Shareholders
Company Information
Uscom Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Uscom Limited
- Ticker: UCM
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$59.048m
- Shares outstanding: 149.49m
- Website: https://www.uscom.com.au
Number of Employees
Location
- Uscom Limited
- 66 Clarence Street
- Suite 2
- Sydney
- New South Wales
- 2000
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| UCM | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Dec 2003 |
| UCM | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Dec 2003 |
Biography
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. It serves hospitals and other medical care locations through a network of distribution partners. The company was incorporated in 1999 and is headquartered in Sydney, Australia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/17 10:35 |
| End of Day Share Price | 2020/02/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.